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Intracranial atherosclerotic disease (ICAD) is likely the most common cause of stroke
worldwide and remains highly morbid even with highly monitored medical therapy. Recent
results of the SAMMPRIS trial, which randomized patients to stenting plus aggressive
medical management versus aggressive medical management alone have shown that addi-
tional treatment of intracranial atherosclerotic lesions with the Wingspan stent is inferior to
aggressive medical management alone. In light of these results, there has been renewed
interest in angioplasty alone to treat symptomatic ICAD. This article will briefly review the
natural history of ICAD and discuss the possible future for endovascular treatment of ICAD
with primary intracranial angioplasty in appropriately selected patients.
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EPIDEMIOLOGY AND NATURAL HISTORY
Several important natural history and medical treatment stud-
ies have been published that allow us to appreciate the impact
of ICAD (1–4). Approximately 5–10% of all strokes and TIA’s
are due to ICAD (5). A landmark, prospective multi-center study
of 4157 patients admitted within 24 h of ischemic onset demon-
strated symptomatic intracranial stenosis (>50%) in 6.5% of
patients (6). The study showed proximal middle cerebral artery
and basilar artery occlusions were seen in 3.7 and 1.2%, respec-
tively (6). Mortality rates at 100 days were highest in the basilar
artery occlusion group (44.7%) and were and 10.1 and 21.4% in
the symptomatic intracranial atherosclerosis (>50%) and mid-
dle cerebral artery occlusion groups, respectively. The incidence of
intracranial atherosclerosis does vary by race and is more prevalent
in Chinese, Japanese, African-American, and Hispanic patients (7,
8), as compared with elevated extracranial atherosclerosis rates in
white patients (9, 10).
The greatest concern for ICAD patients, particularly those with
≥70% stenosis, is the risk of subsequent stroke. While some med-
ical subgroup data suggesting 7–8% stroke rates in untreated
patients with symptomatic stenosis are available from the 1980s
(11), the data are limited by selection bias and inadequate follow-
up. Later studies aimed to address stroke risk (2, 12, 13). In a cohort
of 705 Chinese patients who presented with acute ischemic stroke,
Wong et al. reported 1-year stroke rate of 17.1% in patients with
intracranial atherosclerosis only and 24.3% in patients in patients
with both intracranial and cervical disease. Even more sobering
data were derived in a study by Asil et al. (13) where 13 of 38 (38%)
patients with >50% stenosis who completed 6-month follow-up
had a stroke. Finally, in a study of patients with >50% steno-
sis, the GESICA (Groupe d’Etude des Stenoses Inta-Cranieenes
Atheromateuses symptomatiques) study (2) patients had a 38.2%
rate of a cerebrovascular event during approximately 2 years of
follow-up, in spite of antiplatelet or anticoagulant therapy.
Our best natural history data for ICAD prior to the publi-
cation of the SAMMPRIS trial (4) came from the prospective,
randomized Warfarin-Aspirin Symptomatic Intracranial Disease
(WASID) trial (1). This prospective, multi-center study random-
ized patients to ASA or warfarin. To be included, patients had
to have symptomatic ICAD (>50% narrowing) and the 2-year
primary endpoints were ischemic stroke, brain hemorrhage, and
death from vascular causes. While WASID was criticized for its
non-standard ASA regimen and high rate of dropout for both
medications, warfarin offered no benefit over aspirin in prevent-
ing recurrent stroke, and the primary endpoints were reached in
21% in the aspirin group and 22% in the warfarin group. Notably,
patients in the warfarin arm of the study had significantly higher
rates of hemorrhage and for this reason and the lack of efficacy
WASID was terminated prematurely.
SAMMPRIS targeted a group of high-risk, patients identified
in subgroup analyses of WASID (14–16). This high-risk subgroup
(14) demonstrated a 23% stroke risk at 12 months and was com-
posed of patients with severe stenosis (>70%) enrolled earlier than
17 days after symptom onset. Another subgroup analyses (15, 16)
germane to the construction of SAMMPRIS was the identification
of elevated blood pressure and cholesterol levels as predictive of
future stroke and other vascular events in symptomatic patients
with intracranial stenosis and were the basis of the aggressive
medical management used for both arms of SAMPRISS.
The SAMMPRIS trial (4) randomized patients with sympto-
matic intracranial stenosis (≥70%) to aggressive medical man-
agement versus endovascular therapy with aggressive medical
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management. Enrollment in the trial was halted after 451 patients
underwent randomization because the 30-day stroke and death
rate in the group receiving endovascular therapy and medical man-
agement was 14.7% versus 5.8% in the group receiving medical
management alone. In addition, the probability of experiencing
the primary end point (any stroke or death within 30 days after
enrollment or after any revascularization procedure of a qualifying
lesion or a stroke in the territory of the symptomatic artery beyond
30 days) at 1-year was 12.2% in the medical management group.
It is important to recognize, as stated above, that the importance
of aggressive medical management was derived from the WASID
data (15, 16) and ultimately tested in SAMMPRIS. Aggressive med-
ical management (available to both arms of the SAMMPRIS trial)
consisted of two anti-platelet agents, a statin (goal LDL< 70), and
one medication from each major class of antihypertensive agents
(goal SBP< 140; 130 if diabetic). Patient compliance and risk
factor management were managed at each site by a team includ-
ing a neurologist, a study coordinator, and a lifestyle coach (17).
Compliance with medical regimens was closely monitored by the
study coordinator including counting patients’ anti-platelet med-
ications. The lifestyle coach met with the patients to develop per-
sonal action plans and contacted the patients every 2 weeks for the
first 3 months and then monthly thereafter. Additional help was
provided for difficult-to-manage patients from a central director.
There is little question that aggressive medical management of
ICAD has a profound effect on the natural history of the disease.
While we should try to achieve the medical management parame-
ters set forth in SAMMPRIS, this degree of oversight is costly and
it is quite likely that medical management applied long-term to
“real-world”situations might result in event rates for symptomatic
intracranial stenosis that were higher than those seen in SAMM-
PRIS. In addition, it should be pointed out that the “low” event
rate in SAMMPRIS left more than 1 in 10 patients with a death
or a stroke in the territory of the symptomatic artery at 1 year.
The endovascular comparator in SAMMPRIS was stent placement
with a self-expanding stent and this clearly raises the question
whether another endovascular strategy such as angioplasty alone
may provide better results.
INTRACRANIAL ANGIOPLASTY
Angioplasty used in the setting of symptomatic intracranial steno-
sis has been performed for more than two decades and was
motivated by the poor natural history of ICAD despite medical
therapy. While the first successful intracranial angioplasty was
reported by Thoralf Sundt in 1980, early results showed high
complication rates. For example, Higashida et al. treated eight
symptomatic patients and encountered three major complications
(38%) (18).
Subsequent technical advances reduced these early complica-
tions. One very important contribution to the safety of balloon
angioplasty was the concept of “sub-maximal angioplasty” first
promoted by Connors et al. (19). They examined three time peri-
ods in their angioplasty experience based on the technique used.
In early experience, the angioplasty balloon size approximated the
vessel size with rapid angioplasty. In the middle experience over-
sizing of the balloon was permitted with rapid angioplasty. In
the final time period, an under-sized balloon was used with slow
inflations. Numbers in the groups were small and both variables
(inflation times and balloon size) were not controlled for. Never-
theless, these data indicated procedural complications rates may
be reduced by slow expansion of a balloon smaller than the native
artery.
Table 1 reports the technical success of several groups (19–26)
and suggests the 30-day major complication rates are≤6%. Many
of these same investigators also show low post-procedure stroke
rates over time and this ultimately drives the case for angioplasty in
patients with symptomatic intracranial atherosclerosis (Table 2).
Clark and Yoon demonstrated notable results in studies of 17
and 32 patients, respectively (20, 22) with the latter study report-
ing a single TIA event (Table 2). The two largest series – Marks
et al. (23) and Wojak et al. (24) – also showed favorable stroke
rates. Marks et al. had a 3.2% rate of death and stroke in the terri-
tory corresponding to treatment (42-month follow-up) and Wojak
et al. had an annual stroke rate of 1.8% (45-month follow-up).
Although their follow-up was only 3 months and no annual stroke
rate could be reported, Nguyen et al. (25) had only one stroke in
the territory ipsilateral to the treated vessel. However, four major
procedure-related strokes occurred in this multi-center study.
In a study published in response to SAMPRISS, Dumont et al.
(26) queried their database of 41 patients [many of whom were
ineligible for SAMPRISS and Vitesse Intracranial Stent Study for
Ischemic Therapy (VISSIT)] who underwent intracranial sub-
maximal balloon angioplasty procedures between January 2007
and July 2011. These patients had >70% stenosis and many pre-
sented with an acute ischemic event. In 32 patients with at least
Table 1 |Technical success and 30-day major complications of
angioplasty.
Series N (cohort
size)
Complication
rate (%)
Technical
success (%)
Higashida et al. (18) 8 38
Clark et al. (20) 17 9.1
Marks et al. (21) 23 4.3
Connors et al. (19) 50 6 98
Yoon et al. (22) 32 6 91
Marks et al. (23) 120 5.8 93
Wojak et al. (24) 60 4.8 91
Nguyen et al. (25) 74 5.0 92
Dumont et al. (26) 41 4.9
Table 2 | Long-term stroke rates following angioplasty.
Series N (cohort
size)
Mean follow-up
(months)
Annual stroke
rate (%)
Clark et al. (20) 17 22 0
Yoon et al. (22) 32 20 0
Marks et al. (23) 120 42 3.2
Wojak et al. (24) 60 45 1.8
Nguyen et al. (25) 74 3 N.R.
Dumont et al. (26) 41 12 3.1
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12 months of follow-up, only 1 ischemic event (a TIA) in the vas-
cular distribution of the treated vessel occurred between 30 days
and 1-year after the procedure. However, the 1-year event-free
survival rate was 91% (29 of 32 patients) as two patients had
peri-procedural morbidity.
It cannot escape attention that the angioplasty studies show
substantially lower 30-day peri-procedural complications when
compared to stent treatment arm of the SAMMPRIS study. In
addition, the post-treatment annual stroke rates discussed above
are superior to the natural history reported in those patients
treated with aggressive medical therapy in SAMMPRIS. However,
randomized data comparing a strategy of primary angioplasty
with best medical management alone are lacking.
PATIENT SELECTION AND TECHNIQUE
In our current post-SAMMPRIS practice, we generally follow three
tenets when applying angioplasty to the treatment of sympto-
matic ICAD. The patient should fail best medical therapy (dual
antiplatelet, statins, and risk factor reduction). The operator must
use sub-maximal angioplasty technique. The operator should only
select those lesions likely to respond to balloon dilatation. SAM-
PRISS demonstrated the profound impact of best medical therapy
and we have discussed sub-maximal angioplasty technique. Per-
haps equally important is the issue of lesion selection. Failure
to appreciate the impact of lesion morphology or employ sub-
maximal angioplasty technique would be a serious oversight by
the endovascular surgeon.
Mori et al. (27) hypothesized lesion morphology would affect
lesion response to angioplasty and thus categorized atherosclerotic
lesions as short, concentric and <5 mm long (Mori A), 5–10 mm
long and may be eccentric (Mori B), and >10 mm and may have
excessive tortuosity (Mori C). As predicted, Mori found higher
rates of death, ipsilateral stroke, or subsequent ipsilateral bypass
after angioplasty by lesion type; Type A (8%) versus Type B (26%)
versus Type C (87%). While two studies found no outcome dif-
ferences between lesions >7 or <7 mm (28, 29), a number of
other studies support the Mori data and have found lesion length
or morphology an important variable in determining procedural
success and restenosis rates (30–34).
THE FUTURE OF INTRACRANIAL ANGIOPLASTY
Despite the low 1 year stroke rates following intracranial angio-
plasty, restenosis remains a possible weakness of primary
angioplasty. Symptomatic and angiographic restenosis (23, 24,
26) occur at 6 months in approximately 5–30% of patients treated
with angioplasty alone. The re-angioplasty rate was in excess of
20% in the most recent study in which sub-maximal technique
was rigorously employed.
The drug-eluting balloon (DEB) may alter this problem. The
DEB is an emerging technology with meaningful accumulated data
in coronary arteries and femoropopliteal disease. The sina qua
non-for this technology is effective transfer, absorption, and cir-
cumferentially uniform effect of the drug on the diseased vessel
segment during the short period the balloon is inflated against an
atherosclerotic plaque. Excipient technology (the balloon coating
that helps deliver the drug) is in its infancy and one should expect
a plethora of proprietary formulas in years to come. Paclitaxel
is favored as it is highly lipophilic and allows for passive absorp-
tion through cell membranes with sustained effect within a treated
vessel wall.
Data regarding the use of DEB’s in the small vessels to which we
are accustomed are scant. In a single-arm study, Schmidt et al. (35)
treated patients with infra-popliteal disease and 70% stenosis with
a paclitaxel-eluting balloon (In.Pact Amphirion, Medtronic, Min-
neapolis, MN, USA) with pre-dilatation and 1 min inflation times.
The 3-month restenosis rate (available for 84 of the 109 limbs
treated) was 27.4%, which compares quite favorably with the 60–
70% restenosis rate typically seen with uncoated balloons. There
have been two reports by one endovascular group of DEB use for
intracranial atherosclerotic lesions (36, 37). In their first report,
they compared DEB and conventional angioplasty balloons for the
treatment of in-stent recurrent stenosis and found DEB’s reduced
subsequent restenosis fivefold (9 versus 50%) (36). In their most
recent report, 52 patients with high-grade ICAD lesions under-
went primary angioplasty and stenting with the Enterprise stent.
Angioplasty with the DEB was performed in >80% of patients
and in 33 patients with an average follow-up of 8.9 months only 1
(3%) recurrent stenosis was seen (37).
A possible dilemma for DEB intracranial angioplasty will be
the need to balance “sub-maximal angioplasty” (slow inflation of
under-sized balloons) with effective circumferential coating of the
diseased vessel with excipient and drug. Furthermore, the risk and
consequence of embolization of excipient and drug to intracranial
branches beyond the ICAD lesion is, at present, unknown.
CONCLUSION
The first line of therapy for symptomatic ICAD patients is dual
anti-platelet therapy and aggressive management of blood pres-
sure, blood sugar, and lipids. The SAMMPRIS trial gave us useful
information in that even with aggressive, highly monitored med-
ical management, there is still a concerning 12.2% combined
30-day stroke and death rate or ipsilateral stroke rate beyond
30 days in the first year of treatment. The results of the SAMMPRIS
trial should not stop further investigation of endovascular ther-
apy for severe symptomatic intracranial stenosis. With appropriate
lesion selection and technique, intracranial angioplasty should be
a technically safe procedure with a low complication rate. Fur-
thermore, single center series suggests there is a low annual stroke
rate in these patients. However, no randomized data exists to show
a benefit compared to medical therapy. The impact of DEB’s on
post-treatment stroke rates and restenosis rates is eagerly awaited.
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